



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

6045 '02 MAR 22 P1:1
MAR 21 2002

Robert W. Pollock
Vice President
Lachman Consultant Services, Inc. --
1600 Stewart Avenue
Westbury, NY 11590

Re: Docket No. 01P-0426/CP 1

Dear Mr. Pollock:

I am writing to inform you that the Food and Drug Administration has not yet resolved the issues raised in your citizen petition submitted on September 20, 2001. Your petition requests that the Agency determine whether Oxycontin (Oxycodone Hydrochloride) Extended-Release Tablets 160 mg (NDA 20-553) was withdrawn from sale for safety and efficacy reasons.

FDA has been unable to reach a decision on your petition due to the need to address other Agency priorities. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as possible given the numerous demands on the Agency's resources.

Sincerely yours,

Janet Woodcock, M.D.
Director
Center for Drug Evaluation and Research

01P-0426

LET1